BioAMPS International Receives Phase 2 Contract from Office of Naval Research to Develop New Antibiotic Class for Treatment of Gram-negative Bacteria

Share Article

- Multi-phased contract may provide $1.485 million over three years for development of D-generation peptide drug solution for drug resistant Acinetobacter baumannii in civilian and military patient populations -

Far too few truly unique drug options for the treatment of serious gram-negative bacteria infections are in the industry’s pipeline

BioAMPS International, a biotechnology company dedicated to developing solutions to combat bacterial resistance to conventional antibiotics, announced today that it has received a Phase 2 STTR contract award from the U.S. Office of Naval Research to further develop a peptide-based antibiotic for the treatment of the gram negative bacteria, Acinetobacter baumannii. The multi-phase contract, once successfully executed, will provide total funding of $1.485 million over three years.

BioAMPS International will collaborate on the Phase 2 development program with Dr. Robert Hodges, inventor of the antimicrobial peptide technology, at the University of Colorado, Denver School of Medicine.

The global incidence of A. baumannii, which has developed isolates that are resistant to all current antibiotic treatments, has increased dramatically in both U.S. and European hospitals during the last 10 years, with some areas experiencing five-fold increases. While the bacteria were isolated to injured soldiers in the Mideast in the early 1990’s, the bacterial-resistant strains have evolved into a major healthcare concern for military and civilian institutions worldwide.

“We are excited to enter into this developmental contract with the Navy and look forward to validating a peptide antibiotic drug that may provide a solution to protect the military and civilian patient populations from the debilitating bacteria. Far too few truly unique drug options for the treatment of serious gram-negative bacteria infections are in the industry’s pipeline”, said David A. DeLong, BioAMPS’ chief executive officer.

BioAMPS’ D-generation antimicrobial peptide platform has generated nearly 100 unique analogs that kill gram negative and gram positive bacteria via a mechanism that is equally effective against both drug resistant and non-drug resistant species. Early research suggests that the peptide’s killing mechanism may circumvent bacteria’s ability to develop resistance. The D-generation antimicrobial peptides are relatively small and stable biologic drugs that are capable of being developed as injectable, inhalable or topical formulations, thus, providing potential solutions for topical, inhaled or systemic infections.

About BioAMPS International

BioAMPS International is a privately held, pre-clinical stage company developing a new generation of antimicrobial peptide drugs for the treatment of drug resistant bacteria. The company’s core platform technology generates all D-conformation peptides that overcome the toxicity-related problems of previous generations of all L-conformation peptides. The D-generation peptides offer a potentially new class of antibiotics that can be used as single agents or combined with existing antibiotics to treat multi-drug resistant bacterial infections. The company is based at the Bioscience Park Center, an incubator in the Fitzsimons Life Science District adjacent to the renowned Anschutz Medical Campus in Aurora, Colo. More at

Contact:     David A. DeLong


Share article on social media or email:

View article via:

Pdf Print

Contact Author

David A. DeLong
Visit website